Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 4Azacitidine 3venetoclax 2fludarabine phosphate 2fludarabine 2ON 01910 2Mycophenolic Acid 2Melphalan 2Filgrastim 2Cyclosporine 2Busulfan 2lonafarnib 1itacitinib 1ilorasertib 1exatecan 1darinaparsin 1cedazuridine 1Whole-Body Irradiation 1Transplantation 1Teriparatide 1Radiotherapy 1Piperacillin, Tazobactam Drug Combination 1Peripheral Blood Stem Cell Transplantation 1Parathyroid Hormone 1Methotrexate 1Mesna 1INCB039110 1Granulocyte Colony-Stimulating Factor 1Glycopeptides 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anemia, Refractory, with Excess of Blasts × Glycopeptides × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡